Lunai Bioworks Inc.
RENB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | – | 50% | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2 | $4 | $4 | $4 |
| SG&A Expenses | $2 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $123 | -$0 | $0 |
| Operating Expenses | $3 | $127 | $4 | $5 |
| Operating Income | -$3 | -$127 | -$4 | -$5 |
| % Margin | – | -65,782.8% | – | – |
| Other Income/Exp. Net | $6 | $0 | $4 | -$3 |
| Pre-Tax Income | $3 | -$127 | $0 | -$7 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $3 | -$127 | $0 | -$7 |
| % Margin | – | -65,686.2% | – | – |
| EPS | 0.13 | 2.16 | 0.012 | -0.448 |
| % Growth | -94% | 17,900% | 102.7% | – |
| EPS Diluted | 0.13 | 2.16 | 0.012 | -0.448 |
| Weighted Avg Shares Out | 23 | 165 | 16 | 16 |
| Weighted Avg Shares Out Dil | 23 | 165 | 16 | 16 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$127 | $0 | -$7 |
| % Margin | – | -65,571.8% | – | – |